Last reviewed · How we verify
Ocrevus
At a glance
| Generic name | Ocrevus |
|---|---|
| Sponsor | Kessler Foundation |
| Target | B-lymphocyte antigen CD20 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Primary progressive multiple sclerosis
Common side effects
- Upper respiratory tract infections
- Infusion reactions
- Skin infections
- Lower respiratory tract infections
Serious adverse events
- Serious infections (associated with decreased IgG levels)
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (PHASE3)
- Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis (PHASE4)
- Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis (PHASE4)
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis (PHASE4)
- People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
- Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
- Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (PHASE3)
- Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |